Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Thoracic Malignancies
•
Medical Oncology
Would you consider consolidation immunotherapy after chemoradiation for stage III lung cancer in a patient with history of paraneoplastic autoimmune CNS syndrome that improved with treatment?
Related Questions
Would you consider stopping EGFR inhibitor in EGFR mutant NSCLC on a patient who was NED for >5 years?
What adjuvant therapy, if any, would you offer for a young fit patient with stage IB lung adenocarcinoma harboring an EGFR A763_Y764insFQEA who received no prior therapy?
For those early stage resectable NSCLC patients who received neoadjuvant chemoimmunotherapy as per Checkmate816 and did not attain a pCR, what are the adjuvant immunotherapy treatment strategies if EGFR negative?
Would you consider using IO alone for lung cancer patients who are PDL1 <1 but have high TMB?
Do you think it's appropriate to run separate NGS panels on biopsies from lesions in both the right and left lung in a patient suspected of two lung primaries?
What is the preferred concurrent chemotherapy regimen for limited stage small cell lung cancer with severe reaction to etoposide?
What is your approach for an RA patient with lung cancer who is starting immunotherapy?
How would you manage a patient with stage IV EGFR L858R mutation but with a debilitating drug rash from osimertinib?
Would you consider adjuvant osimertinib for patients with non-classical but sensitizing EGFR mutation positive NSCLC s/p surgical resection?
What is your approach to obtain tissue diagnosis for a patient with a lung primary and spine metastasis?